Cochlear Limited · ASX:COH
Cochlear — Investor Day (November 2026)
132 slides from Cochlear's investor day presentation, Nov 13, 2026
Slide 1: Capital Markets Day 2026: Expanding the future of hearing
Hear now. And always Capital Markets Day 2026 Expanding the future of hearing Dig Howitt Chief Executive Officer & President 13 November 2026
Slide 2: Acknowledgement of Country
Acknowledgement of Country Worimi, Welcome, On behalf of Cochlear, it is a pleasure to acknowledge the Wallumattagal Peoples of the Darug Nation, who are the Traditional Custodians of the Macquarie Park area. We would like to pay respect to Elders, both past and present and to leaders emerging. 2
Slide 3: Agenda
Agenda Dig Howitt Expanding the future of hearing Chief Executive Officer & President Jan Janssen Cochlear’s innovation pipeline Chief Technology Officer Brian Kaplan MD Medicalisation of hearing loss and adjacent therapies Senior Vice President, Global Clinical Strategy & Innovation Dig Howitt US:
Slide 4: Our mission
Our mission We help people hear and be heard. We empower people to connect with others and live a full life. We transform the way people understand and treat hearing loss. We innovate and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes. 4 4
Slide 5: Cochlear reaffirms FY27 guidance
Cochlear reaffirms FY27 guidance: developed market cochlear implant volumes up mid single-digit Jul-Oct FY26 DEVELOPED MARKET KEY DRIVERS REAFFIRMS FY27 GUIDANCE Multiple disruptions and Low single-digit $330-350m EMEA some share loss constant currency sales underlying net profit revenue growth Assu
Slide 6: Revenue has doubled since FY16, with developed market adults driving growth
Revenue has doubled since FY16, with developed market adults driving growth in cochlear implants REVENUE BY SEGMENT (A$M), FY16-FY26 UNDERLYING NET PROFIT (A$M), FY16-FY26 Cochlear implants Services Acoustics 2,356 415 2,343 2,258 387 1,956 322 305 1,641 277 1,493 266 1,446 246 1,351 1,352 224 234 1
Slide 7: Significant opportunity for adult cochlear implant growth
Significant opportunity for adult cochlear implant growth SEVERE TO PROFOUND HEARING LOSS (SPHL): AIDED VS COCHLEAR IMPLANT PENETRATION IN SPHL <5% UNAIDED 1 in 6 people have hearing loss and 1 in 4 over 60 have moderate or higher hearing loss, yet most go untreated or undertreated.1 Profound: 5%2 m
Slide 8: Overcoming barriers along the patient journey
Making hearing implants the standard of care requires overcoming barriers along the patient journey The opportunity is significant. Realising it takes a clear strategy and disciplined execution over many years. Surgical Concerns about Outcome Sound losing residual Aftercare hesitation variability pr
Slide 9: Three strategies, powered by technology and AI, drive earnings growth
Three strategies, powered by technology and AI, drive earnings growth 01 02 03 + Expand access Shape the hearing Transform the Scale growth with to treatment implant category care model technology and AI Medicalise hearing loss and Lead the category through Simplify care, improve Drive cost-effectiv
Slide 10: Our core strategies for growth target these barriers
Our core strategies for growth target these barriers Core strategies Mapping our strategies to delivering 01 Expand access to treatment cochlear implants as the standard of care. 02 Shape the hearing implant category 03 Transform the care model Surgical Concerns about Outcome Sound losing residual A
Slide 11: Expand access to treatment
01 Expand access to treatment Medicalise hearing loss and make implants the standard of care through clear referral pathways. © Cochlear Limited 2026 11
Slide 12: Adults are the long-term growth opportunity: <5% have a CI
Adults are the long-term growth opportunity: <5% have a CI Referral, access and motivation Cochlear implants are the standard of care for infants, with hold back adult treatment penetration rates above 80% across most markets, while penetration rates remain very low for adults. 01 Recognition and re
Slide 13: FY26 highlighted that adult CI needs a more predictable path to surgery
FY26 highlighted that adult CI needs a more predictable path to surgery DEVELOPED MARKET ADULT ENDURING OPPORTUNITY SOFTER FY26 SURGERIES 9% 0% Developed market Developed market adult 10yr CAGR adult growth 9% CAGR to FY25 in FY26 10 yr • Growing awareness and access FY26 showed that patients with s
Slide 14: Professional referral pathways aim to build predictable referral pipelines
Professional referral pathways aim to build predictable referral pipelines US PATIENT PATHWAY TO SURGERY (VOLUME SPLIT) Cochlear-supported ~1/3 Self-navigated ~2/3 MORE CONSISTENT GROWTH SELF-NAVIGATED: MORE VARIABLE GROWTH OUR RESPONSE Stronger professional +10% US Cochlear Supported channel growth
Slide 15: Medicalisation of adult SPHL: evidence and guidelines milestones
Medicalisation of adult SPHL provides the evidence and guidelines to drive advocacy and behavioural change Key Milestones over 10+ years progressing evidence, guidelines, policy and implementation 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Cochlear Chair Cochlear Centre for HHC Landmark Landm
Slide 16: Shape the hearing implant category
02 Shape the hearing implant category Lead the category through innovation and set the benchmark for everyday life with our products. © Cochlear Limited 2026 16
Slide 17: Technology is the core of our competitive advantage
Technology is the core of our competitive advantage This advantage comes from the breadth of our portfolio and is sustained by consistent investment over long periods of time + + Smaller Externals Nexa platform DEE TICI Smart Implants: Drug Eluting Electrodes: Totally Implantable CI: active intellig
Slide 18: Consistently invested ~12% of revenue in R&D
We have consistently invested ~12% of revenue in R&D, with over A$3bn invested since FY00 R&D INVESTMENT (A$M) AND % OF SALES REVENUE, INNOVATION FOCUS AREAS FY00–FY26 13.8% 12.5% 12.1% 12.3% $323m $185m $128m $95m $45m $21m 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Slide 19: Fully implantable technology increases the potential for market growth
Fully implantable technology increases the potential for market growth Consumer research points to potential value beyond hearing performance. Meaningful hearing improvement compared to Better hearing is fundamental high-powered hearing aids remains the foundation for consideration. Reduced day-to-d
Slide 20: Transform the care model
03 Transform the care model Simplify care, improve outcomes, expand capacity and empower recipients. © Cochlear Limited 2026 20
Slide 21: Connected care frees clinic capacity to meet growing demand
Connected care frees clinic capacity to meet growing demand Shifting to proactive, hybrid aftercare cuts appointments and clinical time needed for adults PAST Legacy care model Connected care TOMORROW Optimal care model Connected care tools 10 + 3 in-person appointments after Apps, remote monitoring
Slide 22: Scale growth with technology and AI
+ Scale growth with technology and AI Drive cost-effective scalability and enable growth. © Cochlear Limited 2026 22
Slide 23: Technology and AI turn platform investment into scalable growth
Technology and AI turn platform investment into scalable growth Results are already emerging from a secure core, a connected data and AI platform, and edge AI Benefits already Three-layer strategy Core largely complete AI with control visible A secure core, connected Core systems are AI runs inside
Slide 24: Three contributors build toward our growth ambition
Three contributors build toward our growth ambition CONTRIBUTORS TO GROWTH Financial Financial ambitions ambitions Medicalising hearing loss and streamlining care A predictable referral pathway built through referral programmes and DTC 10% 10% ~ capability, plus a streamlined care model that frees c
Slide 25: Cochlear's innovation pipeline
Hear now. And always Capital Markets Day 2026 Cochlear’s innovation pipeline Jan Janssen Chief Technology Officer 13 November 2026 25
Slide 26: What goals drive innovation at Cochlear?
What goals drive innovation at Cochlear? Help each Help many individual more people reach their to access the full potential technology © Cochlear Limited 2026. 26
Slide 27: Crossing the Chasm
Crossing the Chasm THE CHASM EARLY MARKET MAINSTREAM MARKET © Cochlear Limited 2026. 27
Slide 28: Overcoming barriers along the patient journey
Making hearing implants the standard of care requires overcoming barriers along the patient journey Product Innovation will play a key role Surgical Concerns about Outcome Sound losing residual Aftercare hesitation variability processor size hearing Access & visibility Low barriers awareness 28 © Co
Slide 29: Every breakthrough is built on decades of incremental progress
Every breakthrough is built on decades of incremental progress 1950s 1980s 1990s 2000s Future … Basic Convenience More freedom True freedom What comes next functionality and life integration © Cochlear Limited 2026. 29
Slide 30: Technology is the core of our competitive advantage
Technology is the core of our competitive advantage This advantage comes from the breadth of our portfolio and is sustained by consistent investment over long periods of time + + Smaller Externals Nexa® platform DEE TICI Smart Implants: Drug Eluting Electrodes: Totally Implantable CI: active intelli
Slide 31: Product Innovation is key to Crossing the Chasm
Product Innovation is key to “Crossing the Chasm” THE CHASM EARLY MARKET MAINSTREAM MARKET People more comfortable People who expect adopting earlier generations complete solutions and convenience © Cochlear Limited 2026. 31
Slide 32: Innovation focus areas
Innovation focus areas 01 02 03 04 Hearing Living Connected Portfolio Outcomes my life Care Expansion © Cochlear Limited 2026 32
Slide 33: Closing the gap: real world hearing outcomes
Closing the gap … real world hearing outcomes Speech Cochlear implant Understanding in Quiet recipients still face a Rehabilitation Time & Effort Hearing in Noise gap to normal hearing Adjusting to across multiple cochlear implant outcome measures hearing is a gradual process Speaker Telephone for m
Slide 34: Cochlear implant system overview
Cochlear implant system overview Deep Neural Network Noise Reduction Cochlear Implant System Cochlear Implant Sound Coding Electrode Auditory Brain Front-end array nerve Speech Processing 22-Channel Channel Compression Stimulation Filter Bank Processing Music Auditory Scene Analysis ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ Smar
Slide 35: Nexa smart implants
Cochlear implant system overview Cochlear Implant System Cochlear Implant Sound Coding Electrode Auditory Brain Front-end array nerve Speech Processing 22-Channel Channel Compression Stimulation Filter Bank Processing Music Auditory Scene Analysis ⋮ ⋮ ⋮ ⋮ Nexa ⋮ ⋮ Smartphone Smart Implants: Wireless
Slide 36: The world's first and only smart cochlear implant system
Cochlear® Nucleus® Nexa® System The world’s first and only smart cochlear implant system Nexos Chipset Upgradeable Firmware Internal Memory Enhanced RF Link Onboard Diagnostics Digital Signal Processing Stimulation Flexibility The product images shown are for illustrative purposes only and may not b
Slide 37: Smart Implants benefits today and in the future
Cochlear® Nucleus® Nexa® System Smart Implants benefits today and in the future Ready for the future NEXOS Upgradeable Firmware Chipset The world’s smallest sound Enhanced processors with all day battery1-3*^ RF Link Dynamic Power Management Get back on air quickly Internal MAPs on the implant & Sma
Slide 38: Nexa patients use their smart implant significantly longer
Cochlear® Nucleus® Nexa® System Real-world evidence shows Nexa patients use their smart implant significantly longer “…increased daily device use not only improves audiologic and speech perception but also impacts patient‐reported outcomes as experienced in everyday life.1” © Cochlear Limited 2026.
Slide 39: Smart Implants enabling novel research opportunities
Cochlear® Nucleus® Nexa® System Smart Implants enabling novel research opportunities Monopolar Focused Nexos Chipset Upgradeable Firmware Internal Memory Enhanced RF Link Onboard Diagnostics Cochlear® Nucleus® Nexa® System Digital Signal Processing Stimulation Flexibility (CI1000) Surgical feedback
Slide 40: Optimising the electro-neural interface
Optimising the electro-neural interface • The electro-neural interface (ENI) determines the quality of the connection between the device and the hearing nerve • Foundation for hearing well with a CI • Goal: Deliver clearest sound information to the brain 22 Perimodiolar Nexa Focused Channels electro
Slide 41: Protect neural health and optimise the electro-neural interface
Protect neural health and optimise the electro-neural interface for the individual ear Step 1: Step 2: Do no harm Position well Cochlear’s Slim Modiolar electrode: Positions closest to the hearing nerve Establish a close and Delivers precise stimulation Protect remaining effective connection functio
Slide 42: Perimodiolar electrodes provide superior hearing outcomes
Perimodiolar electrodes provide superior hearing outcomes, a clear source of competitive advantage High-quality evidence consistently demonstrates superior hearing outcomes with perimodiolar electrodes Level 1A clinical evidence published in 2025 by Duckett et 1A al. comprised of a systematic review
Slide 43: Neural health insights could help tailor stimulation
Neural health insights could help tailor stimulation and improve outcomes for each recipient The structure of the Step 1: Step 2: Step 3: individual cochlea Do no harm Position well Understand the individual ear ANATOMY NEURAL HEALTH Establish a close and The pattern and Understand the Protect remai
Slide 44: Neural health can explain up to 50% of CI outcome variability
Neural health can explain up to 50% of CI outcome variability Every patient with Sensori-Neural Hearing Loss has a compromised inner ear, even more so those with severe or profound hearing loss. The number of Spiral Ganglion Cells (SGNs) – which are a measure of neural health – varies widely across
Slide 45: Cochlea health and modiolar proximity combine for superior outcomes
Evidence shows good cochlea health and close modiolar proximity combine for superior CI outcomes Close MODIOLAR PROXIMITY “Optimal speech perception is generally achieved when both cochlear health and modiolar proximity are favourable.”1 Far Poor COCHLEAR HEALTH Good 1Walia, A., Shew, M. A., Smetak,
Slide 46: Nexa with Slim Modiolar electrode gives access to future innovation
Only the Nucleus Nexa implant with a Slim Modiolar electrode gives today’s recipients access to future electro- neural interface innovation Step 1: Step 2: Step 3: Step 4: Step 5: Do no harm Position well Keep an open door to the future Understand the individual ear Personalise stimulation Establish
Slide 47: Focused stimulation: a novel way to deliver sound
Focused stimulation – a novel way to deliver sound Monopolar Stimulation Focused Stimulation • One current source • Multiple current sources tuned to individual and • Broad current spread cochlear place • Reduced spectral resolution • Narrow current spread with adjustable degree of focus • Can work
Slide 48: Focused NRT reveals neural health, with 4x predictive power
Focused NRT reveals each recipient's neural health, with 4x the predictive power Focused Neural Response Telemetry (NRT) lets us investigate the unique neural health pattern of the individual cochlear implant user. The combination of Modiolar Proximity measurements and Focused NRT enables us to crea
Slide 49: Nexa with Slim Modiolar: future potential for today's recipients
Only the Nucleus Nexa implant with a Slim Modiolar electrode gives today’s recipients access to future electro- neural interface innovation Step 1: Step 2: Step 3: Step 4: Step 5: Do no harm Position well Keep an open door to the future Understand the individual ear Personalise stimulation Establish
Slide 50: Focused stimulation can improve hearing in noise
Focused stimulation can improve hearing in noise Hearing in noise remains one of the biggest challenges Focused Stimulation Benefit (MP-FMS SRT) for cochlear implant users. 3 2 A pilot study comparing monopolar and focused stimulation demonstrated up to 2.3 dB improvement 1 in the Speech Reception T
Slide 51: Focused stimulation can improve listening to music
Focused stimulation can improve listening to music Listening to music requires fine spectral and temporal resolution. Focused stimulation improves spectral precision by reducing current spread. Focused Stimulation Monopolar Stimulation In two pilot studies, 21 out of 31 participants preferred Focuse
Slide 52: Drug eluting electrodes provide a new way to protect the cochlea
Drug eluting electrodes provide a new way to protect the cochlea Step 1: Step 2: Step 3: Step 4: Step 5: Do no harm Position well Keep an open door to the future Understand the individual ear Personalise stimulation Establish a close and Choose a smart Understand the Customise Protect remaining effe
Slide 53: The human cochlea is a complex and delicate structure
The human cochlea is an amazingly complex and delicate structure Perimodiolar electrodes have evolved Contour Advance (x12) Slim Modiolar (x32) © Cochlear Limited 2026. 53
Slide 54: Drug eluting electrode: long-term stability and cochlear health
Drug eluting electrode: designed for long-term device stability and protection of cochlear health Long-term impedance reduction Hearing preservation Slim Modiolar DEE2 Contour Advance DEE1 Slim Modiolar DEE2 2014 2021 1. Briggs R, O 'Leary S, Birman C, et al. Comparison of electrode impedance measur
Slide 55: Drug eluting electrodes reduce fibrosis in large animal model
Drug eluting electrodes reduce fibrosis in large animal model Minipig with regular CI electrode Minipig with drug eluting CI electrode © Cochlear Limited 2026. Thin Sheet Light Imaging Microscopy - TSLIM 55
Slide 56: Innovation focus areas
Innovation focus areas 0 01 02 03 04 Hearing Living Connected Portfolio Outcomes my life Care Expansion © Cochlear Limited 2026 56
Slide 57: Living your life: evolving the external components
Living your life – evolving the external components Behind-The-Ear (BTE) Off-The-Ear (OTE) Continue to shrink the No external processor Sound Processors Sound Processors Sound Processor (TICI) © Cochlear Limited 2026. 57
Slide 58: Why develop TICI?
Why develop TICI? Opportunity to make more people Opportunity to better meet chose a CI over a high power hearing candidate expectations. aid. Provide CI users the ability to hear in all environments, 24/7: Feeling safer Freedom detect alarms & warnings in all environments to pursue life with fewer
Slide 59: Challenges developing a totally implantable cochlear implant
Challenges developing a totally implantable cochlear implant When moving the external elements of the CI system into the body, new challenges need to be overcome: The body becomes a more explicit part of the 01 acoustic environment. Microphone Battery Placing an implanted battery into the body 02 me
Slide 60: 20+ years of experience developing a TICI: 1st generation
More than 20 years of experience and learn in developing a TICI 2005 – 1st generation Key learnings: 1st Gen. Freedom to hear in any situation is transformative TICI 01 even with a relatively immature solution. Battery longevity must be designed in the entire 02 system. 2005 Study* (n = 3) 03 Body n
Slide 61: Developing solutions to tackle the most significant challenges
Developing solutions to tackle the most significant challenges 2018 – 2nd generation Key learnings: 2nd Gen. Effective body noise management increases patient TICI 01 satisfaction dramatically. 02 Surgery and fitting time are essential for scalability. 2018 Study* (n = 10) 03 Reliability is paramoun
Slide 62: Continuing to evolve the technology: 3rd generation
Continuing to evolve the technology with further enhancements 2024 – 3rd generation Key learnings: 3rd Gen. Further enhancements in body noise management TICI 01 continue to increase patient satisfaction. No BNC With BNC 02 No BNC With BNC Reduced implant size simplifies surgery. 2024-2026 Studies*
Slide 63: TICI offers the possibility to exceed patient expectations
TICI offers the possibility to exceed patient expectations 92 patients implanted with 3rd generation TICI device across Australia, 92 Europe and USA in two pivotal studies ENTERPRISE and ELEVATE. Both studies are contributing to more than two decades of accumulated 20+ clinical learning with invisib
Slide 64: Innovation focus areas
Innovation focus areas 0 01 02 03 04 Hearing Living Connected Portfolio Outcomes my life Care Expansion © Cochlear Limited 2026 64
Slide 65: Cochlear Connected Care is transforming hearing health care
Cochlear Connected Care is a transforming hearing health care In-clinic Care Remote Care Surgical Care Connected Patient Self-managed Care © Cochlear Limited 2026. 65
Slide 66: Cochlear Surgical Care solutions
Cochlear Surgical Care solutions are designed to improve the surgical experience and patient outcomes through intraoperative tools, providing greater confidence in device placement and clinical performance. Surgical Care © Cochlear Limited 2026. 66
Slide 67: Surgery: intraoperative measurements and data transfer
Login Login with Professional Account Login with Professional account Impedance and AutoNRT® Surgery Perform intraoperative measurements Finalization Placement check Data transfer (Cloud or file export) Angular Insertion Depth Speed of Insertion 67 © Cochlear Limited 2026.
Slide 68: Using Nexa's smarts to help patients hear sooner
Using Nexa’s smarts to empower patients and help them hear sooner Sound processor placed Under clinician At home, patient Activation MAP saved on head (Smart Sync) to implant at surgery supervision, patient adjusts MAP with patient On Air increases loudness App with App It is beneficial that patie
Slide 69: Seamless and secure data transfer from surgery to fitting
Seamless and secure data transfer from surgery to fitting Intraoperative data from Nucleus SmartNav can be transferred seamlessly to Custom Sound Pro via the secure Cochlear Cloud to assist in the CI fitting process Nucleus® SmartNav System Custom Sound Pro © Cochlear Limited 2026. 69
Slide 70: Cochlear In-clinic Care solutions
Cochlear In-clinic Care solutions improve patient management and care, giving the clinician the time and flexibility to optimise every appointment. In-clinic Care © Cochlear Limited 2026. 70 70
Slide 71: In-clinic Care | Custom Sound Pro
In-clinic Care | Custom Sound Pro Custom Sound Pro Fitting Uses surgery, fitting and performance data Software for Nucleus® and Intuitive layouts and guided workflow Kanso® Sound Processors Maximises achieving the right fit for each patient for clinicians Data-driven Design Flexible fitting Pa
Slide 72: Cochlear Remote Care
Cochlear Remote Care enable clinicians to deliver quality care and monitor patients remotely, while patients can conveniently access care through their smartphone, wherever they are. Remote Care © Cochlear Limited © Cochlear 2023. Limited D2107128_EMEA_Connected Care Overview 2026. 72
Slide 73: Enroll: clinician enrolls recipient into Remote Care
myCochlear Professional Enroll Clinician enroll recipient into Remote Care Implant site photos Questionnaire Part 1 Aided Audiogram Perform Remote Check Implant Check Recipient performs Remote Check using the Nucleus Smart App Speech in Noise Questionnaire Part 2 Hardware Health Usage Data Review an
Slide 74: Remote Check review and Remote Assist live session
Remote Check review Schedule Clinician and recipient fix an appointment Custom Sound Pro Clinician joins Remote Assist session, counsels through video and can make certain MAP adjustments. Remote Assist live session Nucleus Smart App Recipient joins Remote Assist session © Cochlear Limited 2026. thr
Slide 75: Cochlear Self-managed Care solutions
Cochlear Self-managed Care solutions empower patients in partnership their clinician to proactively manage their hearing experience in daily life through their smartphones. Self-managed Care © Cochlear Limited 2026.
Slide 76: Self-managed Care | Nucleus Smart App
Self-managed Care | Nucleus Smart App Apple or Android compatible Nucleus Smart App Pair with device for Nucleus 7, Nucleus 8 Adjust settings and Kanso 2 patients Check status Access to other remote services Adjust settings Access to Device status check Find my processor Hearing tracker Re
Slide 77: Cochlear Connected Care is transforming hearing health care
Cochlear Connected Care is a transforming hearing health care In-clinic Care Remote Care CochlearTM Connected Care delivers data driven insights enabling personalized care and optimised recipient outcomes Surgical Care Connected Patient Self-managed Care © Cochlear Limited 2026. 77
Slide 78: Innovation focus areas
Innovation focus areas 0 01 02 03 04 Hearing Living Connected Portfolio Outcomes my life Care Expansion © Cochlear Limited 2026 78
Slide 79: Technology and partner network are foundations for adjacent indications
Cochlear’s leading technology and partner network are strong foundations to explore adjacent indications 7th generation head-based neurostimulation Highly trusted brand, with global academic platform with outstanding reliability and network and partnerships functionality Minimally invasive head-base
Slide 80: Opportunity to help more people progress at every step
At every step on the journey to standard of care, we see an opportunity to help more people progress Product Innovation will play a key role Surgical Concerns about Outcome Sound losing residual Aftercare hesitation variability processor size hearing Access & visibility Low barriers awareness TICI D
Slide 81: Medicalisation of hearing loss and adjacent therapies
Hear now. And always Capital Markets Day 2026 Medicalisation of hearing loss and adjacent therapies Brian Kaplan MD SVP Global Clinical Strategy & Innovation 13 November 2026
Slide 82: Medicalisation of hearing loss
Medicalisation of hearing loss Making hearing health a core responsibility of healthcare WORKING DEFINITION Establishing hearing loss as a clinically consequential health condition and embedding its prevention, identification, diagnosis, treatment, and ongoing management into routine healthcare, wit
Slide 83: Cochlear implants became the standard of care for children by 2010
Cochlear implants became the standard of care for children by 2010 Clinical evidence supporting the benefits of bilateral Development of health economic data implantation. By 2010, 50% of supporting cost effectiveness of cochlear children under 3 receive two implants for children implants (70% by 20
Slide 84: Medicalisation of adult SPHL: evidence and guidelines milestones
Medicalisation of adult SPHL provides the evidence and guidelines to drive advocacy and behavioural change Key Milestones over 10+ years progressing evidence, guidelines, policy and implementation 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Cochlear Chair Cochlear Centre for HHC Landmark Landm
Slide 85: Standardising hearing care will drive more referrals
Standardising hearing care will drive more referrals, with more consistent conversion Medicalisation focus areas – considering the journey Key examples of progress to date for CI (FY18-26) of other disease states (e.g., obesity) • Consensus statements and Global Living Guidelines for Define hearing
Slide 86: ICD codes and HL stages: establishing treatment triggers
ICD codes and HL stages example: Establishing treatment triggers for hearing loss to transform treatment The challenge: Most diseases have coded stages leading to clinical action. Hearing loss has no equivalent trigger making it impossible to automate the referral pathway and limiting reimbursement
Slide 87: The strengthening link between hearing and cognition
The strengthening link between hearing and cognition What we’ve already learnt regarding cognition The growing evidence base on the horizon HL is one of the largest potentially modifiable risk factors Social, cognitive, physical outcomes and economics of CI for dementia - Lancet Commission (2024
Slide 88: New health economic evidence expands ROI of cochlear implants
New health economic evidence expands ROI of cochlear implants to support health system priorities CIs were already cost effective; additional evidence shows this was under-estimated. Modelling including risk of falls, cognition and mortality of CI vs Hearing Aids in UK adults ≥50 years old with SPHL
Slide 89: The strengthening link between hearing and falls risk
The strengthening link between hearing and falls risk Hearing and balance are both controlled in the inner ear and changes in one can affect the other. What we’ve already learned regarding falls The growing evidence base on the horizon HL has been shown to impact mobility, balance and associated wit
Slide 90: Technology and partner network are foundations for adjacent indications
Cochlear’s leading technology and partner network are strong foundations to explore adjacent indications 7th generation head-based neurostimulation Highly trusted brand, with global academic platform with outstanding reliability and network and partnerships functionality Minimally invasive head-base
Slide 91: Early clinical evidence in bilateral vestibulopathy
Encouraging early clinical evidence in bilateral vestibulopathy, a disabling balance disorder with no therapeutic alternatives What is bilateral vestibulopathy (BVP)? BionicVEST collaboration • Severe balance impairment, including chronic dizziness, visual • Strong academic collaborations with EU fu
Slide 92: Cochlear US: Expanding professionally supported pathways to growth
Hear now. And always Capital Markets Day 2026 Cochlear US: Expanding professionally supported pathways to growth Dig Howitt Chief Executive Officer & President 13 November 2026
Slide 93: US overview: a large, ageing and under-treated market
US overview: a large, ageing and under-treated market where awareness, access and closing the referral gap unlock growth turn 65 every day1 10,000+ ‘New’ 65-year-olds join the US senior segment daily. Senior growth runs at 3.5x the pace of the general population (2020–35), reaching 23.4% of the popu
Slide 94: The adult segment is our biggest long-term opportunity in the US
The adult segment is our biggest long-term opportunity in the US and now accounts for almost 80% of CI surgeries Growth depends on clearer referrals and capacity to treat Segment mix – US* Low penetration 21% 31% ~6% of US adults with severe to profound hearing loss have a cochlear implant5 79% 69%
Slide 95: US adult patient journey
US adult patient journey 100 will get referred to a CI clinic 45 will surgically qualify In every 1000 people who have severe to 800 have hearing 35 will be profound hearing loss aids implanted 60 will be evaluated for a CI Developing a consistent, clinically led referral pathway for adults is key t
Slide 96: Referral demand generation occurs across various channels
Referral demand generation occurs across various channels, with varying degrees of Cochlear engagement Total addressable market 1 Patient funnel Ageing populations and wider indications have expanded the market, led by people seeking care for severe to profound Total SPHL addressable market (TAM) he
Slide 97: Direct-to-consumer campaigns and professional partnerships drive growth
Over more than a decade, our direct-to-consumer campaigns and professional partnerships have driven strong growth and expanded to ~1/3 of surgeries in the US each year Total SPHL addressable market (TAM) Direct to Consumer (Digital) Seeking care for SPHL (80% of TAM) Cochlear engages directly with
Slide 98: US DTC Programs: expanding qualified demand
US DTC Programs – Expanding qualified demand American Association of Retired Persons (AARP) magazine: Healthy Aging Campaign: Multi-channel, 6-week pilot that Print ad in U.S.’s largest magazine targeting adults 50+ (11m confirmed that hearing health/healthy messaging resonated circulation). The ad
Slide 99: Professional referrals as a sustainable long-term growth engine
Professional referrals offer a potentially more sustainable long term growth engine enabled by the medicalisation of hearing loss Patient funnel Total SPHL addressable market (TAM) Seeking care for SPHL (80% of TAM) Medical Channel The referral to the CI centre originated from a medical centre fro
Slide 100: Direct-to-Professional pilots in the US
Direct-to-Professional pilots in the US connect hearing and medical professionals to local CI centres to grow medical referrals 1. Identify growth markets with motivation and capacity to grow 2. Pilot Therapy Development Identify priority pilot markets based on concentration Program in target market
Slide 101: APAC: Expanding access and reshaping the category
Hear now. And always Capital Markets Day 2026 APAC: Expanding access and reshaping the category Stu Sayers President Asia Pacific & Latin America 13 November 2026
Slide 102: Expanding access and reshaping the implant category in APAC
Expanding access to treatment and reshaping the implant category are where APAC is driving growth. Today’s Focus 01 02 03 Expand access to treatment Shape the implant category Transform the care model Medicalise hearing loss and make implants the standard Lead the category through innovation and set
Slide 103: GAMA sets the playing field and our activity widens the funnel
Government Affairs Market Access (GAMA) sets the playing field + Our activity can widen the candidate funnel + Nexa® + Osia® wins share SHAPING THE IMPLANT CATEGORY 1 2 Accelerating referrals 3 GAMA Australia – A more connected journey is helping more adults China: we are reach surgery sooner adapti
Slide 104: GAMA: achieving access, pricing and new category designations
GAMA sets the playing field: Achieving access, pricing and new category designations Three reimbursement initiatives finalised across Korea, Japan and Australia, setting new categories and premium pricing. 1 Osia® 2 Nexa® System 3 Baha® 7 KOREA & JAPAN JAPAN AUSTRALIA ~80% 5% 5% premium over Baha ®
Slide 105: Australia: funding for under 26s and private insurance; caps and gaps
Australia: Good funding for those under 26 and/or on Private Insurance. Caps and gaps for adult/senior Public patients 65+ replacement funding in Public is top short term GAMA priority in Australia Fully funded Partially funded Not yet funded Implant system Implant system Sound processor replacement
Slide 106: Australia: a more connected journey supports more adults reaching surgery
AUSTRALIA – A more connected journey is supporting more adults reach surgery sooner Private is where the growth is: motivation of surgeon and candidate are the biggest drivers ~70% of surgeries come from ‘self navigated’* 66% of FY26 surgeries are private (50% of population) Flat public surgeries Yo
Slide 107: Australia grew private surgeries +15% through funnel focus
Australia was able to grow private surgeries +15% through ‘Cochlear Supported’ and ‘Self Navigated’ funnel focus Over time the pathway has shifted from late, fragmented identification to earlier referral, active navigation and lifelong support. THEN Late recognition › Hearing aid pathway › Unclear r
Slide 108: Australia and the US are ~5-10 years ahead of Japan and Korea
Australia and the US are ~5-10 years ahead of Japan and Korea, and their learnings are exportable SHARED CONTEXT • Heavily urbanised, ageing populations (AU 28M, KR 50M, JP 120M) ~5-10 yrs ahead Australia United States South Korea Japan • CI largely well reimbursed • Cochlear share 70%–90%, but ~80
Slide 109: Korea: shift in focus toward market growth is starting to work
Korea: Signs that the shift in focus more toward market growth is starting to work Broadening the funnel via Australian market learnings and developing next tier 1 Outpacing the CI market 2 Increasing the team’s focus on 3 Results growth Annual CI units, FY22–FY26 Impact of new surgeons and the shif
Slide 110: Japan: building hub-and-spoke referral networks
Japan is poorly served for hearing: Our focus is on building hub-and-spoke referral networks around receptive centres Growth focus is building networks around the CI centres with high awareness and motivation 1 CHALLENGE 2 CHALLENGE 3 RESPONSE 4 RESULTS Japan's hearing health is Funnel drop-out is h
Slide 111: China: adapting well to a fast-changing market
China: we are adapting well to, and learning from, a fast-changing market 1 We have executed well to adapt in a fast- (a) MARKET MIX BY AGE GROUP changing market 6% 13% 21% 2 We’ve grown share and now hold a clear 59% leadership position Cochlear share +10% from pre VBP* 94% 87% 79% 40% 3 The market
Slide 112: APAC driving growth and share through Nexa and Osia launches
APAC driving growth and share in every country by leveraging Nexa® and Osia® launches NEXA LAUNCHES Australia Korea Japan India AGM (Singapore, Malaysia, Thailand, Vietnam) Launch: June 2025 Launch: April 2026 Launch: June 2026 Launch: April 2026 Launch: June 2025 – April 2026 across countries Share
Slide 113: EMEA: Clear pathway to sustainable long-term growth
Hear now. And always Capital Markets Day 2026 EMEA: Clear pathway to sustainable long- term growth Anthony Bishop President EMEA 13 November 2026
Slide 114: EMEA: a large, under-treated, growing market
EMEA: a large, under-treated, growing market Millions of candidates, few implanted, and a hearing-care market that keeps expanding: the gap is our growth runway. ATTRACTIVE MARKET FUNDAMENTALS SYSTEM FORCES RESHAPING EMEA >$5bn ~6.5% ~ 15.2m 1 Aging population 20% of the EU is aged 65+ [7]; Age-rela
Slide 115: Cochlear EMEA: many diverse markets, one goal
Cochlear EMEA: many diverse markets, one goal: Help People Hear Faster 30+ Languages Multiple local-language requirements across commercial, clinical and regulatory activity 5 Key markets Germany Balanced go to UK market model Spain Italy France 72 A region spanning different healthcare realities DE
Slide 116: EMEA Growth Flywheel
EMEA Growth Flywheel Expand Four reinforcing levers convert unmet demand need into sustainable growth SUSTAINABLE Lead EMEA GROWTH Accelerate through Treatment innovation More people hear. More value created. Medicalisation of hearing loss Shape Access Demand Treatment Access Innovation 116
Slide 117: Expand Demand: Direct to Consumer in Germany
Demand Treatment Access Innovation Expand Demand: Direct to Consumer (DTC) in Germany: Expanding the candidate pool DTC drives market growth DTC builds awareness, drives earlier action and expands the qualified CI candidate pipeline. In Germany, ~1 million of the 10 million people with hearing loss
Slide 118: Accelerating Referrals: partnering to expand demand
Demand Treatment Access Innovation Accelerating Referrals: Partnering to expand demand In France, we are partnering with Hearing Aid professionals who can refer eligible candidates into the implant pathway Use the hearing aid patient pathway to identify and support implant patients Simple, clear, an
Slide 119: Accelerating Treatment: Professional Education
Demand Treatment Access Innovation Accelerating Treatment: Professional Education From individual courses to a connected, measurable and scalable learning ecosystem. • Faculty Excellence: A broad pool of professional faculty • Learning pathways: Face-to-face, online and self-paced learning across in
Slide 120: Accelerating Treatment: freeing up clinical capacity
Demand Treatment Access Innovation Accelerating Treatment: Freeing up clinical capacity Continue to innovate how we create Capacity on the ground Exploring new territory for Surgical Capacity 1000’s of hours of clinical (audiology) capacity freed up thanks to our care pathway workshops across EMEA*
Slide 121: Shape Access: GAMA informing policies through evidence and advocacy
Demand Treatment Access Innovation Shape Access: GAMA - Informing policies through evidence-generation, consensus building and advocacy • COACH Study: Randomised trial of cochlear implantation Evidence Generation vs hearing aids in adults with bilateral SNHL who fall outside current NHS/NICE criteri
Slide 122: Leading through innovation: translating Nexa momentum into growth
Demand Treatment Access Innovation Leading through innovation: Translating Nexa momentum into sustainable growth “This new system allows you much more than anything before so that you can 1 DRIVING MARKET ENGAGEMENT really participate in what’s coming next.” Prof. Dr. Thomas Lenarz, ENT Clinic Direc
Slide 123: Lead through innovation: the new Osia 3 Sound Processor
Demand Treatment Access Innovation Lead through innovation: The new Osia 3 Sound Processor Win market share Expand the category Capture upgrades Aim to position Osia as the Unlock new demand Making the benefits of benchmark in active through Baha-to-Osia Osia 3 versus Osia 2 clear bone conduction vs
Slide 124: Technological foundations and growth enablers
Hear now. And always Capital Markets Day 2026 Technological foundations and growth enablers Karen O’Driscoll Chief Information Officer 13 November 2026
Slide 125: Our Technology Strategy
Our Technology Strategy Three layers, one strategy: a secure and stable core, a connecting data and AI platform, and edge technologies work together to drive cost-effective scalability and enable growth. What it includes Key benefits • Data products • Fast and cost-effective to build and deploy Edge
Slide 126: Our Technology Transformation Journey
Our Technology Transformation Journey Core systems transformation is substantially complete. Investment is now shifting to edge technologies, where we can drive significant gains in efficiency and effectiveness enabling better experiences and scalable growth. FY24 FY25 FY26 FY27 FY28 + Back-office s
Slide 127: Empowering innovation and retaining control
Empowering Innovation and retaining control Our eco-system balances innovation and control: AI tools sit on a governance layer and inside our walled garden, so we can scale AI across the business safely and under control. All employees can use AI to experiment and drive personal productivity, our pr
Slide 128: Artificial Intelligence delivering tangible benefits
Artificial Intelligence delivering tangible benefits AI is already delivering measurable results, and the next 12 months scale it further. Our transformation pods are driving gains in productivity, decision-making and conversion at speed. Who it serves The people AI helps Surgeon Hearing health prof
Slide 129: Demonstration of AI capability: Digital Avatars
Demonstration of AI capability – Digital Avatars We can now provide our customers access to curated knowledge through various channels where they can interact using natural language and speech. This allows people to access information in real-time and in their own language, scaling our reach and imp
Slide 130: Forward looking statements and Glossary
Forward looking statements Glossary Cochlear advises that this document contains forward- Slide 15 and 84 looking statements which may be subject to significant COACH - landmark RCT trial investigating whether adults who fall just uncertainties outside of Cochlear’s control. No outside current NHS /
Slide 131: References (I/II)
References (I/II) Expanding the future of hearing (slides 1 to 24) Medicalisation of hearing loss and adjacent therapies (slides 81 to 91) 1. WHO 2021 World Report on Hearing (https://www.who.int/activities/highlighting-priorities-for- 1. Conrad P. Medicalisation and Social Control. Annual Review of
Slide 132: References (II/II)
References (II/II) 3. WHO 2021 World Report on Hearing (https://www.who.int/activities/highlighting-priorities- 14. Lin FR, Ferrucci L. Arch Intern Med. 2012;172(4):369-371. for-ear-and-hearing-care) 15. Haddad YK, et al., Inj Prev. 2024; 30(4):272-276. 4. Lin FR et al. Hearing intervention versus h